{
    "id": "85338960-904b-44df-908f-b74b62902779",
    "indications": "camzyos® indicated treatment adults symptomatic new york heart association ( nyha ) class ii-iii obstructive hypertrophic cardiomyopathy ( hcm ) improve functional capacity symptoms .",
    "contraindications": "must individualized based status echocardiographic assessment patient response . refer full prescribing information instructions . ( 2.1 )",
    "warningsAndPrecautions": "camzyos® supplied immediate release size 2 hard gelatin capsules containing 2.5 mg , 5 mg , 10 mg , 15 mg mavacamten . white opaque capsule bodies imprinted “ mava ” , opaque cap imprinted strength . capsule contains white off-white powder . camzyos capsules available bottles 30 capsules , listed table : strength capsule cap ndc number 2.5 mg light purple 73625-111-11 5 mg yellow 73625-112-11 10 mg pink 73625-113-11 15 mg gray 73625-114-11 storage store 20°c 25°c ( 68°f 77°f ) , excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "camzyos contraindicated concomitant : • strong cyp2c19 inhibitors [ ( 5.2 ) , ( 7.1 ) ] •moderate strong cyp2c19 inducers moderate strong cyp3a4 inducers [ ( 5.2 ) , ( 7.1 ) ]",
    "ingredients": [
        {
            "name": "MAVACAMTEN",
            "code": "QX45B99R3J"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Myokardia, Inc.",
    "name": "CAMZYOS",
    "effectiveTime": "20250417",
    "indications_original": "CAMZYOS® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.",
    "contraindications_original": "Dosage must be individualized based on clinical status and echocardiographic assessment of patient response. Refer to the Full Prescribing Information for instructions. ( 2.1 )",
    "warningsAndPrecautions_original": "CAMZYOS® is supplied as immediate release Size 2 hard gelatin capsules containing 2.5 mg, 5 mg, 10 mg, or 15 mg of mavacamten. White opaque capsule bodies are imprinted with “Mava”, and the opaque cap is imprinted with the strength. The capsule contains white to off-white powder. CAMZYOS capsules are available in bottles of 30 capsules, as listed in the table below:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Capsule Cap\n                              \n                           \n                           \n                              \n                                 NDC Number\n                              \n                           \n                        \n                        \n                           \n                              2.5 mg\n                           \n                           \n                              Light purple\n                           \n                           \n                              73625-111-11\n                           \n                        \n                        \n                           \n                              5 mg\n                           \n                           \n                              Yellow\n                           \n                           \n                              73625-112-11\n                           \n                        \n                        \n                           \n                              10 mg\n                           \n                           \n                              Pink\n                           \n                           \n                              73625-113-11\n                           \n                        \n                        \n                           \n                              15 mg\n                           \n                           \n                              Gray\n                           \n                           \n                              73625-114-11\n                           \n                        \n                     \n                  \n                  \n                     Storage \n                  \n                  Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "CAMZYOS is contraindicated with concomitant use of:\n                  \n                     \n                        •\n                        Strong CYP2C19 inhibitors [see \n                        \n                        \n                           Warnings and Precautions (5.2)\n                           , \n                           Drug Interactions (7.1)\n                           ]\n                        \n                     \n                     \n                        •Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers [see Warnings and Precautions (5.2), Drug Interactions (7.1)]"
}